Ferroplex

Quick links to important sections

Ferroplex

Selected form

Method of action: Antianemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferroplex

Quick Facts

Property Description
Active Ingredients Ferrous Sulfate, Sodium Ascorbate
Form Oral Tablet
Pharmacological Class Hematinic Agent, Vitamin and Mineral Combination
General Purpose Support for Iron Balance and Blood Formation
Origin Synthetic Salts

The medicinal entity Ferroplex is a combination product used to address specific nutritional needs, formally classified under the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system as a Hematinic Agent. This oral preparation functions as a specialized Vitamin and Mineral Combination, supplying the necessary components to support the formation of healthy blood cells and maintain the body's essential iron stores.


What Type of Medicine is Ferroplex?

Ferroplex is typically marketed as an accessible supplement product, making it readily available for common nutritional support. It is a synthetic pharmaceutical preparation, supplied most often as an oral tablet intended for systemic absorption via the digestive tract. It is defined as a combination product because it contains two distinct active chemical entities rather than a single ingredient. The product's classification as a Hematinic Agent places it among the medicines specifically used to improve blood quality and support the production of red blood cells.


Composition: Ferrous Sulfate and Sodium Ascorbate

The core composition of Ferroplex features the active ingredients Ferrous Sulfate and Sodium Ascorbate (a salt of Ascorbic Acid, or Vitamin C). Ferrous Sulfate is the chemical salt that supplies elemental iron, an essential body mineral critical for forming the oxygen-carrying protein, hemoglobin. The product’s design, combining the mineral with the vitamin, is clinically recognized for significantly improving the body's capacity to absorb the supplied ferrous iron. The Sodium Ascorbate is a deliberate inclusion to serve as an absorption enhancer to optimize the mineral uptake.


General Purpose: Support for Iron Balance

The general purpose of Ferroplex is to aid in the efficient restoration of the body's iron balance and provide necessary support for hematopoiesis (blood formation). The combination is specifically used in scenarios where iron requirements are increased, such as during pregnancy or periods of high dietary restriction. The overall goal is to facilitate the processes required for new red blood cell production, helping the body ensure efficient oxygen transport throughout tissues.

Regulatory References

  1. NIH Office of Dietary Supplements Iron Fact Sheet

What side effects are possible with Ferroplex?

Possible Side Effects and Safety Information

Agranulocytosis and Neutropenia Risk

The most serious safety concern documented for Ferroplex (deferiprone) is the risk of agranulocytosis, a severe reduction in white blood cells that can lead to life-threatening infections and death. Neutropenia, a lower but still serious reduction in neutrophils (a type of white blood cell), may precede agranulocytosis. Due to this risk, the Absolute Neutrophil Count (ANC) must be measured before starting therapy and monitored weekly during treatment. The drug is contraindicated in patients with a history of repeatedly developing neutropenia or agranulocytosis.

Common Adverse Reactions

The most commonly reported adverse reactions (occurring in ge 5% of patients in clinical trials) primarily involve the gastrointestinal and musculoskeletal systems, and laboratory investigations:

  • Gastrointestinal: Nausea, vomiting, abdominal pain/discomfort.
  • Musculoskeletal: Arthralgia (joint pain).
  • Investigations: Alanine Aminotransferase (ALT) increased, Neutropenia, and Chromaturia (reddish-brown urine discoloration), which is an expected, non-harmful effect of the drug's mechanism.

Warnings and Precautions

  • Hepatotoxicity: Liver enzyme levels (ALT/AST) must be monitored monthly during therapy, as clinically significant increases have been observed.
  • Embryo-fetal Toxicity: Ferroplex can cause fetal harm and is contraindicated in pregnant women and those who are breastfeeding. Females of reproductive potential must use effective contraception during treatment and for at least six months after the last dose; males should use contraception for three months after the last dose.
  • Zinc Deficiency: Decreased plasma zinc concentrations have been observed, requiring regular monitoring.
  • Drug Interactions: Co-administration with other medications known to cause neutropenia or agranulocytosis should be avoided.

Overdose and Emergency Response

Overdose and when to seek help

This section details officially documented overdose information, symptoms, and mandated emergency actions for iron compounds, which form the primary toxic risk of Ferroplex.


Documented Overdose Manifestations

Overdose often presents initially with severe gastrointestinal distress, including excessive vomiting, which may be bloody (hematemesis), and profuse diarrhea. Systemic effects include rapidly developing low blood pressure (hypotension) and rapid heart rate (tachycardia). As toxicity progresses, patients may exhibit lethargy, drowsiness, confusion, and develop metabolic acidosis.


Life-Threatening Outcomes and Emergency Actions

Official regulatory documents classify iron overdose as a life-threatening risk due to the potential for systemic shock and delayed progression to acute liver failure and neurological issues like seizures and coma. This necessitates the guidance to seek immediate medical attention and contact emergency services immediately following a suspected overdose, even if the individual initially appears well. Urgent help is explicitly required if the patient has collapsed or has an altered level of consciousness.


Antidote and Management

Regulatory information confirms that Deferoxamine is the specific chelating agent indicated for the management of severe systemic iron toxicity. Supportive measures such as whole-bowel irrigation are documented for gastrointestinal decontamination. Hospital monitoring and assessment of serum iron concentration are required for all significant ingestions. Iron overdose is a leading cause of fatal poisoning in children under the age of six, emphasizing the need for immediate intervention.

Therapeutic Uses of Ferroplex

Quick Facts: Ferroplex Therapeutic Domains

Purpose Condition Management
Primary Use Managing iron-deficient states
Therapeutic Target Iron deficiency anemia
Key Benefit Replenishing the body's iron stores and supporting hemoglobin synthesis

Ferroplex is a prescription medication utilized in the management of iron deficiency in adults. The drug is indicated for therapeutic use when the body's iron stores are low, which can lead to a condition known as iron deficiency anemia (IDA). This condition may arise from various factors, including inadequate iron intake through diet, conditions causing chronic blood loss, or increased physiological needs for iron, such as during pregnancy.

The primary function of Ferroplex is to help replenish the necessary iron levels within the body. Sufficient iron is essential for the production of hemoglobin, which is a protein in red blood cells that helps transport oxygen throughout the body. By addressing the underlying iron deficiency, the medication may support the maintenance of adequate red blood cell count and overall oxygen transport function.

Treatment with an appropriate iron product, like Ferroplex, is a key component in restoring iron balance and may lead to an improvement in symptoms associated with low iron levels. Ensuring proper iron levels is a fundamental aspect of managing iron-deficient states and supporting red blood cell health.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Ferriprox

Official regulatory documents define strict criteria for the use of Ferriprox (deferiprone), primarily based on the patient's existing health status and demographics.

Populations Who Must NOT Use This Medicine (Contraindications)

Condition/Status Eligibility Classification
Hypersensitivity to deferiprone Contraindicated
History of Recurrent Neutropenia or Agranulocytosis Contraindicated
Pregnancy or Breastfeeding Contraindicated

Conditional Use and Restrictions

Therapy must be interrupted in patients who develop neutropenia (Absolute Neutrophil Count below 1.5 imes 10^9/L). Special caution and monitoring are required for patients with severe hepatic or renal impairment.

Age-Related Eligibility: Tablets are indicated for patients 8 years of age and older, while the Oral Solution is for patients 3 years of age and older.

Reproductive Status: Women of reproductive potential must use effective contraception during treatment and for a minimum of six months after the last dose. Use is not established for treating iron overload in patients with Myelodysplastic Syndrome or Diamond Blackfan Anemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ferroplex (Ferrous Sulfate and Sodium Ascorbate) primarily documents pharmacokinetic interactions resulting from chelation and altered absorption in the gastrointestinal tract. This profile necessitates restrictions and timing separation for co-administered agents.

Official Interaction Restrictions

Classification Official Regulatory Constraint
Contraindicated Combination Co-administration with Parenteral Iron Preparations is restricted and contraindicated as oral iron may inhibit the efficacy of the intravenous form.
Timing Separation Requirement Mandatory administration separation is required for all chelation-susceptible medications to mitigate reduced systemic exposure.

Exposure-Modifying Substances

Ferroplex may reduce the systemic exposure (plasma concentration) of several co-administered medicines, including Tetracyclines, Quinolones, Levothyroxine, Bisphosphonates, and Mycophenolate Mofetil. The official prescribing information documents that Antacids reduce the absorption of Ferroplex's iron component, and therefore, their administration must be separated. The absorption of iron is also officially reduced by certain dietary components, such as calcium supplements, polyphenols/tannins found in coffee and tea, and phytates.

Mechanism of Action

How Ferroplex Works

Ferroplex works by supplying elemental iron, an essential mineral cofactor necessary for key biological processes. The mechanism is defined by a three-stage approach: targeted delivery, systemic transport, and cellular utilization within the hemoglobin synthesis pathway.


Targeted Gastrointestinal Iron Delivery

This phase focuses on how the specific Iron Protein Succinylate (or similar complex) formulation acts to modulate the release of Fe^2+. The complex remains stable and protected within the acidic environment of the stomach, releasing the elemental iron only upon reaching the less acidic conditions of the small intestine. This regulated release mechanism provides a specific Fe^2+ concentration gradient to the intestinal mucosa, influencing Fe^2+ precipitation and complex formation kinetics at the gastric and duodenal mucosa, ensuring the iron is presented to the specialized transport proteins.


Hemoglobin Synthesis and Oxygen Transport Pathway

Once absorbed into the bloodstream, the iron is immediately bound to transferrin for systemic transport and delivery to target cells, primarily in the bone marrow. Here, the iron is internalized via the transferrin receptor and facilitates the incorporation of Fe^2+ into the protoporphyrin ring to generate heme, the essential component of the hemoglobin molecule. This mechanistic step increases the quantity of newly synthesized hemoglobin capable of O2 binding.

Dosage and Administration Information

Ferroplex is a modified-release oral tablet containing Ferrous Sulfate and Sodium Ascorbate, and its proper use is defined by specific administration instructions. The medication is restricted to the oral route only.


Official Dosing and Frequency

Feature Official Instruction Summary
Route of Administration Oral only
Standard Adult Dose One tablet daily for both therapeutic and prophylactic use
Dosing Frequency Once daily (Q.D.)

Administration and Handling Constraints

For the modified-release formulation to function as intended, the tablet must be swallowed whole with water and must not be crushed, chewed, or sucked. This handling constraint is a critical requirement for maintaining the controlled release mechanism. The tablet may be taken before meals or during meals, depending on the individual's gastrointestinal tolerance.

Course Duration and Adjustments

Treatment with Ferroplex typically follows an intermediate-duration course. The daily regimen is generally continued for an extended period, which may last three to six months after the primary markers of iron deficiency, such as hemoglobin levels, have normalized. This extended course aims to fully replenish the body's iron storage reserves.

Use of this specific product is subject to age-group rules: the modified-release formulation is officially not recommended for children under 12 years of age. If a dose is missed, instructions are to skip the forgotten dose and take the next dose at the regular scheduled time; double dosing is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ferroplex

Research Evidence for Iron Deficiency Anemia (IDA)

Research exploring the active components in Ferroplex primarily focuses on individuals with Iron Deficiency Anemia (IDA). The research examined the product, combining Ferrous Sulfate and Sodium Ascorbate, to evaluate iron status in diagnosed individuals. This research relies on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Studies explored short-term changes in iron status in various populations, often focusing on adults with IDA. Trials report how biomarkers, such as Hemoglobin (Hb) and Serum Ferritin (iron stores), evolved. These findings contextualize how the product was studied for changes in iron status.

Evidence Comparing the Combination to Iron Only

Some clinical trials compared the combined iron and Ascorbic Acid formulation against iron supplementation alone. The goal was to explore whether adding Ascorbic Acid was associated with different reported patterns in outcomes related to systemic imbalance. Findings were mixed across some studies; some evidence suggests a change in absorption patterns, while others indicate that the two groups may appear to share similar outcomes on key blood measures.

Studies Examining Iron Requirements During Pregnancy

Research has also examined the product's components in populations that often present with increased iron needs, such as pregnant women. Studies monitored changes in maternal Hemoglobin and other iron markers. While iron supplementation in pregnancy has been extensively studied, the research specifically for this two-component formulation is more limited, and the certainty about the necessity of the added Vitamin C component remains low in some published reports.

Long-Term Evidence and Durability of Effect

The majority of the research conducted in the research record was studied for short-term monitoring. Follow-up durations were limited, usually lasting only a few weeks up to three to six months. Long-term effects are not fully established. Research does not determine whether an individual's replenished iron stores can remain stable for an extended period after supplementation stops.

Gaps in Evidence and Areas of Uncertainty

The research highlights areas where certainty remains low. Evidence quality varies across studies, especially in trials attempting to isolate the effect of the two components versus the iron component alone. The findings were mixed regarding the role of the Ascorbic Acid (Vitamin C), particularly in certain populations.

Key Studies & References

  1. Cosupplementation of iron and vitamin C for anemia - Study Summary of a Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Ferroplex (FAQ)


Q: Is Ferroplex safe to use during pregnancy?

A: Ferrous sulfate is an active ingredient commonly used to manage iron deficiency in pregnant women. Official sources indicate its use is frequent to prevent or treat anemia during pregnancy, when recommended by a healthcare professional.


Q: Can children take Ferroplex, and is there a specific formulation for them?

A: Regulatory information indicates that the modified-release tablet form of ferrous sulfate is not recommended for children under 12 years of age. For younger children requiring iron, there are typically lower-dose formulations, such as liquid drops, available. Such use is determined by a healthcare provider.


Q: Do you have to take Ferroplex with food?

A: Regulatory information states the tablet can be taken either before meals or during meals. Taking it with food is a common practice to minimize potential gastrointestinal discomfort, although optimal absorption may vary.


Q: Is it true that iron supplements like Ferroplex can stain teeth?

A: Yes, official guidance advises that to prevent the risk of tooth discoloration, the tablet should be swallowed whole with water without sucking or chewing. Contact with the mouth's surfaces may lead to temporary tooth discoloration or irritation.


Q: Is Ferroplex used for conditions other than iron-deficiency anemia?

A: The product is officially indicated for the prevention and treatment of iron deficiency. This broad goal aims to support iron balance in the body, not strictly limited to treating the full clinical condition of anemia.


Q: Are there any specific laboratory tests required before starting Ferroplex?

A: Clinical practice guidelines recommend that a healthcare provider assess the patient’s blood work before starting treatment. This assessment helps confirm the presence of low iron levels or iron deficiency anemia to justify the treatment.


Q: Is Ferroplex used to treat low ferritin levels?

A: Official monitoring guidelines state that serum ferritin (which indicates iron stores) is a key biomarker tracked, alongside hemoglobin, to assess the effectiveness of the iron treatment over time.


Q: How quickly should I expect to feel a difference after starting Ferroplex?

A: Clinical guidance suggests that an increase in hemoglobin (the oxygen-carrying protein) is typically measurable in blood tests after approximately three to four weeks of consistent supplementation. Subjective feeling of improvement may vary.


Q: Is it normal to feel a bit nauseous when taking Ferroplex?

A: Yes, official regulatory documents list nausea and abdominal pain or discomfort as commonly reported adverse reactions associated with taking oral iron supplements.


Q: Is it better to take Ferroplex in the morning or at night?

A: The product information states the tablet can be taken at any time. While some sources suggest morning administration may influence absorption, the most important factor is consistent daily use, as directed by a healthcare professional.


Q: What is the difference between Ferroplex and other generic iron pills I can buy?

A: Ferroplex is a modified-release tablet containing a combination of Ferrous Sulfate (iron) and Sodium Ascorbate (Vitamin C). This combination and formulation are designed to influence iron absorption, distinguishing it from generic iron pills which may use a different iron salt or lack the added Vitamin C.


Q: What are the signs that Ferroplex is actually working for my iron deficiency?

A: While a healthcare provider tracks blood markers, a patient may notice an improvement in common symptoms of iron deficiency. These often include reduced fatigue and increased energy levels after several weeks of consistent use.


Q: Are there any long-term side effects associated with taking Ferroplex for a long time?

A: The typical course of treatment described in regulatory guidance is generally continued for three to six months after iron levels normalize. Long-term effects beyond this established course are not fully detailed in the official research record.


Q: Can I take multivitamins that contain iron while I'm on Ferroplex?

A: Co-administration with other oral iron preparations, such as those found in many multivitamins, is generally discouraged. This is generally discouraged due to the risk of exceeding safe iron intake levels when taking multiple oral iron sources simultaneously.


Q: Is it normal to feel more energetic a few weeks after starting Ferroplex?

A: Yes, as the iron stores are gradually restored and hemoglobin production improves, patients using the product may notice an improvement in symptoms commonly associated with iron deficiency, such as fatigue and low energy.


Q: Are there certain medical conditions that would prevent someone from taking Ferroplex?

A: Yes, the product is contraindicated for people with conditions that cause iron overload, such as Haemosiderosis or Haemochromatosis. It is also typically avoided in people with certain types of anemia or active gastrointestinal diseases like a peptic ulcer.


Q: Does Ferroplex cause any changes in appetite?

A: Some product labels for ferrous sulfate, the active iron ingredient, list decreased appetite as a possible side effect, particularly when used in younger populations.


Q: What's the difference in absorption when Ferroplex is taken with orange juice versus water?

A: The combination of iron with the Ascorbic Acid salt is designed to optimize absorption. Some clinical discussions mention that taking iron with additional sources of Vitamin C, such as orange juice, may further influence absorption.


Q: Can alcohol consumption interfere with Ferroplex?

A: Although regulatory labels may not specifically list alcohol, drug interaction databases linked to official sources list alcohol (ethanol) as a potential interaction that may interfere with the effectiveness or absorption of iron products.


Q: Why does Ferroplex sometimes irritate the stomach lining?

A: The metallic iron component, even in its modified form, can be irritating or damaging to the sensitive lining of the gastrointestinal tract (mucosa). This is a common characteristic of oral iron supplements, leading to side effects like abdominal pain and nausea.


Q: Is it important to monitor other vitamins like B12 while on Ferroplex?

A: Official precautions advise that co-existing deficiencies of vitamins, such as Vitamin B12 or Folic Acid, should be ruled out, as these deficiencies must also be managed by a healthcare professional.


Q: What are the common signs of an allergic reaction to Ferroplex?

A: Signs of an allergic reaction to iron products, though uncommon, can include a rash, hives, itching, wheezing, throat tightness, or swelling of the face, mouth, or tongue. These symptoms are serious and would require immediate communication with a healthcare professional.


Q: Why is my doctor checking my iron levels a few weeks after starting Ferroplex?

A: Healthcare professionals monitor iron levels to assess the product’s effect. Official guidance recommends tracking biomarkers like serum ferritin and hemoglobin every few months to confirm the treatment is effectively building the body's iron stores.


Q: Why do some people experience metallic taste after taking iron supplements like Ferroplex?

A: A metallic taste in the mouth is listed in product information as a potential, though temporary, side effect associated with the use of oral iron supplements.

How should Ferroplex be stored and disposed of?

How to Store and Dispose of Ferroplex

Official regulatory guidelines mandate specific conditions for storing and discarding Ferroplex (Ferrous Sulfate and Sodium Ascorbate tablets) to ensure stability and safety.

Storage Requirements:

Ferroplex must be stored at a Controlled Room Temperature of 20^circ to 25^circC (68^circ to 77^circF) and must be protected from light, moisture, and freezing. Keep the medication in its tightly closed original container.

Mandatory Safety Constraint:

It is critically important to keep this product out of the sight and reach of children. The official label includes a strict warning that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six.

Disposal Instructions:

Do not dispose of Ferroplex by flushing it down the toilet or pouring it into a drain. Unused or expired medication should be disposed of through a recognized drug take-back program or by following official guidance for mixing the tablets with an undesirable substance before discarding them in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ferroplex found in:

A-Z Index: